

# Association of systemic and intra-articular osteoclastogenic potential, pro-inflammatory mediators and disease activity with the form of inflammatory arthritis

---

Ikić, Marina; Jajić, Zrinka; Lazić, Elvira; Ivčević, Sanja; Grubišić, Frane; Marušić, Ana; Kovačić, Nataša; Grčević, Danka

Source / Izvornik: *International Orthopaedics*, 2014, 38, 183 - 192

Journal article, Accepted version

Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)

<https://doi.org/10.1007/s00264-013-2121-0>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:105:533262>

Rights / Prava: [In copyright](#) / [Zaštićeno autorskim pravom](#).

Download date / Datum preuzimanja: **2025-04-02**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine Digital Repository](#)





## Središnja medicinska knjižnica

**Ikić M., Jajić Z., Lazić E., Ivčević S., Grubišić F., Marušić A., Kovačić N., Grčević D. (2014) *Association of systemic and intra-articular osteoclastogenic potential, pro-inflammatory mediators and disease activity with the form of inflammatory arthritis*. International Orthopaedics, 38 (1). pp. 183-92. ISSN 0341-2695**

<http://www.springer.com/journal/264>

<http://link.springer.com/journal/264>

<http://dx.doi.org/10.1007/s00264-013-2121-0>

<http://medlib.mef.hr/2331>

University of Zagreb Medical School Repository

<http://medlib.mef.hr/>

**Association of systemic and intra-articular osteoclastogenic potential,  
proinflammatory mediators and disease activity with the form of inflammatory  
arthritis**

Marina Ikić<sup>1,2</sup>, Zrinka Jajić<sup>3</sup>, Elvira Lazić<sup>4</sup>, Sanja Ivčević<sup>1</sup>, Frane Grubišić<sup>3</sup>, Ana Marušić<sup>5</sup>, Nataša Kovačić<sup>1</sup>,  
Danka Grčević<sup>1,6</sup>

<sup>1</sup>Laboratory for molecular immunology, University of Zagreb School of Medicine, Salata 12, Zagreb-HR  
10000, Croatia

<sup>2</sup>University Hospital “Holy Ghost”, Department of Clinical Immunology and Rheumatology, University of  
Zagreb School of Medicine, Sveti Duh 64, Zagreb-HR 10000, Croatia

<sup>3</sup>Clinical Hospital Center “Sisters of Mercy”, Department of Rheumatology, Physical Medicine and  
Rehabilitation, University of Zagreb School of Medicine, Vinogradska cesta 29, Zagreb-HR 10000, Croatia

<sup>4</sup>General Hospital “Dr. Ivo Pedišić”, Department of Dermatology and Venereology, J.J.Strossmayera 59,  
Sisak-HR 44000, Croatia

<sup>5</sup>Department of Research in Biomedicine and Health, University of Split School of Medicine, Soltanska 2,  
Split-HR 21000, Croatia

<sup>6</sup>Department of Physiology and Immunology, University of Zagreb School of Medicine, Salata 3b, Zagreb-  
HR 10000, Croatia

Correspondence to: Danka Grcevic, Department of Physiology and Immunology, University of Zagreb School  
of Medicine, Salata 3b, 10000 Zagreb, Croatia, Phone:+38514566 944, Fax:+38514590 222, E-mail address:  
[danka.grcevic@mef.hr](mailto:danka.grcevic@mef.hr)

## Abstract

**Purpose:** We aimed to assess osteoclastogenic potential of peripheral blood mononuclear cells (PBMC) and synovial fluid-derived mononuclear cells (SFMC) in different forms of arthritis and to correlate it with inflammatory mediators within intra-articular and circulatory compartments.

**Methods:** Parallel PBMC and SFMC samples of patients with rheumatoid arthritis (RA; n=10) and psoriatic arthritis (PsA; n=10), and PBMC of healthy controls were cultured to assess osteoclastogenic potential by the number of tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts (OCs) and expression of OC-related genes (receptor activator of nuclear factor- $\kappa$ B (*RANK*), *cFMS*, and *TRAP*). Osteoclastogenesis was correlated with the arthritis-related inflammatory indicators in serum and synovial fluid (SF).

**Results:** Number of OCs differentiated from PBMC was significantly higher in RA and PsA compared with control, with RA having more OCs compared with PsA. There was no difference in SFMC OC number between arthritic patients, but *RANK* expression in OCs differentiated from SFMC was higher in PsA compared with RA. SF of PsA patients more potently induced OC differentiation from control CD3<sup>-</sup>CD19<sup>-</sup>CD56<sup>-</sup>CD11b<sup>+</sup>CD115<sup>+</sup> PBMC compared with RA, paralleled with higher *RANK-ligand* expression in PsA SFMC. Positive correlations of OC number with erythrocyte sedimentation rate, serum level of CCL2, and PBMC gene expression of *interleukin-18* and *Fas-ligand* were observed.

**Conclusion:** Osteoclastogenic potential is systemically enhanced in patients with RA, paralleled by disordered systemic and local expression of proinflammatory mediators, whereas PsA involves specific deregulation in RANKL/RANK axis. Our study reveals arthritis-specific mediators associated to the form of arthritis, indicating clinical relevance for diagnosis and treatment.

Key words: rheumatoid arthritis, psoriatic arthritis, osteoclasts, cytokines, inflammation, bone loss, peripheral blood, synovial fluid

## Introduction

Inflammatory arthritides comprise a heterogeneous group of joint disorders that are characterized by chronic inflammation, and intra-articular and generalized bone loss due to deregulated bone homeostasis; bone resorption by osteoclasts (OCs) and bone formation by osteoblasts [1]. Erosions of periarticular bone are the central feature of rheumatoid arthritis (RA) and also occur in spondyloarthritis (SpA) and erosive form of osteoarthritis [2].

Development of bone erosions is critically dependent on OCs, capable of resorbing the mineralized matrix. OCs are multinuclear cells derived from mononuclear osteoclast progenitors (OCPs) of the monocyte-macrophage lineage, which can be matured *in vitro* in the presence of macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor- $\kappa$ B ligand (RANKL) [1, 3]. OCPs are found in the peripheral blood (PB) and synovial tissue of patients with RA and SpA [4], mediating bone loss locally, in the form of bone erosions and joint osteolysis, and systemically, with the loss of bone mineral density (BMD) [5]. Under pathological conditions associated to arthritis, the process of osteoclastogenesis is markedly enhanced by various osteoclastogenic factors, including proinflammatory cytokines (interleukin (IL)-1, IL-6, IL-17, IL-18, tumor necrosis factor  $\alpha$  (TNF- $\alpha$ )), chemokines (such as CC-chemokine ligand 2 (CCL2), CCL3, CCL4), and apoptotic mediators (Fas-ligand (FasL), TNF-related apoptosis-inducing ligand, ligand for herpesvirus entry mediator) [6, 7]. It has been shown that even a small rise in the level of systemic inflammation can precipitate osteodestruction, leading to fractures and disabilities related to arthritis [2, 8].

Although the enhanced osteoclastogenesis and osteoresorption have been confirmed in several forms of arthritis, relative contribution of systemic versus local changes to OC differentiation and activity has not been fully revealed. Moreover, discrimination criteria between forms of arthritis, regarding the mechanisms of osteoclastogenic response and key osteoclastogenic factors, have not been fully defined. The major aim of our study was to correlate the osteoclastogenic potential of peripheral blood mononuclear cells (PBMC) and synovial fluid-derived mononuclear cells (SFMC) with the parameters of systemic inflammation as well as circulating and intra-articular levels of proinflammatory/immunoregulatory mediators. In addition, we aimed to identify disease-specific factors that discriminate between control and arthritic subjects, and are best associated with osteoclastogenic potential, form of arthritis and disease activity.

## **Patients and Methods**

### *Patients*

A total of 20 patients with the following diseases: RA (n=10) and psoriatic arthritis (PsA) (n=10), admitted to the Rheumatology Department of the Clinical Hospital Center “Sisters of Mercy”, were included in the study after obtaining approval from the Ethics Committee and informed consent from patients (Table 1). The study was conducted in accordance with the Declaration of Helsinki. RA was diagnosed according to the revised American College of Rheumatology (ACR) criteria and PsA according to the Moll and Wright criteria. Paired synovial fluid (SF) and PB samples were obtained from RA and PsA groups, age and sex matched, which were further evaluated using the standard clinical variables (listed in Supplementary table 1) and laboratory parameters (C-reactive protein (CRP; mg/L), measured by standard nephelometric assay and erythrocyte sedimentation rate (ESR; mm/h), determined according to the Westergren method) (Table 1). PB samples of the age and sex matched control subjects (Ctrl) admitted due to non-inflammatory conditions, with normal values for inflammatory indicators (ESR and CRP; Table 1) and without history of autoimmune or joint diseases, were used for enzyme-linked immunosorbent assay (ELISA) (n=14) and OC cultures (n=8). Patients with RA and PsA significantly differ from controls in the systemic indicators of inflammation (ESR and CRP; Table 1).

### *Osteoclast differentiation*

SF of arthritic patients was aspirated during therapeutic puncture of the affected knee. PB of arthritic patients and control subjects was obtained as a part of routine clinical assessment. PBMC and SFMC were separated, using Histopaque (Sigma-Aldrich, St. Louis, MO, USA).

Isolated PBMC and SFMC were plated in  $\alpha$ -minimal essential medium ( $\alpha$ -MEM) supplemented with 10% fetal bovine serum (FBS). After 24 hours non-adherent cells were harvested and plated ( $3.5 \times 10^5$  cells/well in 96-well plate) over a glass coverslips in the presence of 40 ng/mL recombinant human (rh)M-CSF and 60 ng/mL rhRANKL for additional 8 days [4]. OCs were identified as tartrate-resistant acid phosphatase (TRAP)-positive cells with  $\geq 2$  nuclei/cell. OC differentiation was additionally confirmed by the expression of

OC-specific genes; receptor activator of nuclear factor- $\kappa$ B (*RANK*), macrophage colony-stimulating factor receptor (*cFMS*, CD115) and *TRAP* using quantitative (q)PCR.

#### *Gene expression analysis by qPCR*

Total RNA was extracted from PBMC/SFMC and OC cultures using TRIzol (Invitrogen by Life Technologies (LT), Grand Island, NY, USA), converted to complementary DNA and amplified in duplicates by qPCR in an ABI Prism 7500 Sequence Detection System (Applied Biosystems by LT). Gene expression of OC-specific genes (*RANK*, *cFMS*, *TRAP*) and proinflammatory/immunoregulatory mediators (*TNF- $\alpha$* , *IL-17*, *IL-18*, *FasL*, *RANKL*) was assessed using TaqMan Assays (Applied Biosystems by LT) (Supplementary table 2) and presented as RNA relative quantity as previously described [7].

#### *ELISA*

The serum and SF concentrations of TNF- $\alpha$  (Quantikine High Sensitivity Immunoassay, R&D systems, Minneapolis, MN, USA), CCL2, IL-17, FasL (Quantikine Immunoassay, R&D systems), and IL-18 (Quantikine Immunoassay, Medical & Biological Laboratories Co., LTD, Naka-ku, Nagoya, Japan) were determined in accord to the manufacturer instructions. Optical density was determined within 15 minutes on the microplate reader (Bio-Rad, Hercules, CA, USA) set to excitation wavelength at 450 nm (for CCL2, IL-17, IL-18, and FasL) or 490 nm (for TNF- $\alpha$ ).

#### *Cell sorting and co-culture*

PBMC of healthy volunteers (n=5) were pooled and labeled using the lymphoid (CD3/CD19/CD56) and myeloid markers (CD11b and CD14). OCPs were defined as CD3<sup>-</sup>CD19<sup>-</sup>CD56<sup>-</sup>CD11b<sup>+</sup>CD14<sup>+</sup> cells and sorted using BD FACSAria I (BD Biosciences, Franklin Lakes, NJ, USA), with sorting purity >98%. Sorted cells (50000/cm<sup>2</sup>) were cultured in  $\alpha$ -MEM/10% FBS supplemented with rhRANKL and rhM-CSF (20 ng/mL for both). Additionally, SF of individual RA and PsA patients was added in 40% volume proportion to assess its osteoclastogenic potential.

### *Statistical analysis*

Clinical data were presented as mean±standard deviation (SD). OC number and gene expression values were expressed as median with the interquartile range (IQR) and compared using non-parametric Kruskal-Wallis test followed by Mann-Whitney test with Bonferroni's correction for multiple testing. Correlations were assessed by Spearman's coefficient rho ( $\rho$ ) with its 95% confidence interval (CI). Receiver-operating characteristic (ROC) curve analysis was presented as area under the curve (AUC) with its 95% CI, and used to discriminate between arthritic and control group. Statistical analysis was performed using the MedCalc software package (Mariakerke, Belgium). For all experiments,  $\alpha$ -level was set at 0.05.



## Results

### *Enhanced osteoclastogenic potential in arthritic patients*

Number of TRAP-positive OCs differentiated from PBMC of patients with RA and PsA was significantly higher compared with control (RA vs ctrl  $p=0.008$ , PsA vs ctrl  $p<0.001$ ; Fig. 1a and b), with the most prominent osteoclastogenic potential in RA (RA vs PsA  $p=0.043$ ; Fig. 1b). In parallel, expression of *RANK* and *TRAP* was higher in freshly isolated PBMC (day 0) from RA and PsA patients, but reached the statistical significance only for *RANK* in PsA compared with control ( $p=0.003$ ; Fig. 1c).

In contrast, there was no significant difference in the number of TRAP-positive OCs differentiated from SFMC (Fig. 1a and b). Nevertheless, SFMC derived OCs from PsA patients were morphologically different (larger with more nuclei/cell; Fig. 1a). Gene expression for *RANK* and *TRAP* in freshly isolated SFMC (day 0) of PsA patients was higher compared with RA, but did not reach statistical significance (Fig. 1c).

OC differentiation was confirmed by the increase in the expression of OC-specific genes with the duration of osteoclastogenic cultures from arthritic patients (comparison of day 0 (white bars) and day 10 (grey bars); Fig. 1c), particularly for *RANK* and *TRAP*. We found more than 3-fold higher *RANK* expression at the OC-culture end-point for PBMC (day 10) of RA compared with PsA ( $p=0.004$ ; Fig. 1c), and more than 5-fold higher *RANK* expression for SFMC (day 10) of PsA compared with RA ( $p=0.048$ ; Fig. 1c).

### *Association of systemic and intra-articular osteoclastogenic potential in arthritis*

To determine the profile of soluble systemic and local osteoclastogenic factors, we selected  $\text{TNF-}\alpha$ , CCL2, IL-17 and IL-18, and assessed them in PB and SF at both protein and gene expression levels (Fig. 2a and b). Overall, concentrations of selected inflammatory mediators were higher in SF than in serum, with RA SF having the peak values for CCL2,  $\text{TNF-}\alpha$  and IL-17 (Fig. 2a).

Serum concentration of CCL2 was significantly higher in RA patients compared with control ( $p=0.016$ ; Fig. 2a) and positively correlated with the number of OCs derived from PBMC ( $p=0.036$ ; Fig. 3). For  $\text{TNF-}\alpha$ , we could not find statistically significant difference at the protein or gene expression level between groups, although the values were highest for SF of RA patients (Fig. 2a). Serum levels of IL-17 in patients with PsA were elevated compared with controls (PsA vs ctrl,  $p=0.013$ ) as well as in SF of RA patients compared with

PsA ( $p=0.054$ ) (Fig. 2a). Gene expression of *IL-18* in PBMC was significantly higher in all forms of arthritis compared with controls (RA vs ctrl,  $p<0.001$ ; PsA vs ctrl,  $p<0.001$ ; Fig. 2b). At the protein level, IL-18 was the most prominent in both serum and SF of RA patients, but the difference was not statistically significant (Fig. 2a). Furthermore, statistically significant positive correlation was observed between the *IL-18* PBMC gene expression and PBMC OC number ( $p=0.049$ ; Fig. 3).

In addition, we found increased gene expression of *FasL* in PBMC of patients with PsA compared with control ( $p=0.003$ ; Fig. 2b) as well as positive correlation between both soluble FasL concentration in sera ( $\rho=0.412$ , 95% CI 0.067 to 0.669,  $p=0.024$ ; not shown) and *FasL* PBMC gene expression ( $p=0.017$ ; Fig. 3) with the number of PBMC derived OCs.

Finally, we functionally tested the osteoclastogenic potential of SF by co-culture of sorted OCPs (defined as  $CD3^-CD19^-CD56^-CD11b^+CD14^+$  population) in osteoclastogenic media containing 40% volume proportion of the individual SF from RA or PsA patients (Fig. 4a). In that model we confirmed significantly more efficient osteoclastogenesis in co-cultures treated with PsA SF compared with RA SF ( $p=0.040$ ; Fig. 4b). Moreover, PsA patients had significantly higher *RANKL* expression in SFMC ( $p=0.042$ ; Fig. 4c) but similar in PBMC compared with RA patients (Fig. 4c).

#### *Correlation between osteoclastogenic potential and indicators of inflammation*

ESR, indicator of chronic systemic inflammation, positively correlated with the number of differentiated OCs from PBMC ( $p=0.023$ ; Fig. 3). However, we could not confirm significant correlations with osteoclastogenic potential for other clinical variables, probably due to the small group size. Furthermore, we subdivided the patients regarding the sulphasalazine (SSZ) treatment, used as a disease-modifying antirheumatic drug, and found that they had significantly reduced levels of FasL ( $p=0.013$ , respectively, Mann-Whitney test) in SF ( $n=10$ ) compared with patients not receiving SSZ ( $n=10$ ).

ROC curve analysis revealed that the control and patient groups could be distinguished based on the number of *ex vivo* matured OCs (AUC=0.921, 95% CI 0.750 to 0.987,  $p<0.001$ ), serum level of CCL2 (AUC=0.697, 95% CI 0.499 to 0.852,  $p=0.045$ ), and PBMC gene expression of *IL-18* (AUC=1.000, 95% CI 0.871 to 1.000,  $p<0.001$ ) and *FasL* (AUC=0.793, 95% CI 0.594 to 0.923,  $p=0.001$ ) (Fig. 5).

In contrast, there was no significant correlation between the SF osteoclastogenic mediators or circulatory indicators of inflammation and the number of differentiated OCs from SFMC, suggesting that SF represents the specific compartment that is locally regulated by infiltrating immune cells. Nevertheless, we found the significant positive correlation between *CCL2* gene expression in SFMC osteoclastogenic culture end-point (day 10) and number of differentiated OCs ( $\rho=0.546$ , 95% CI 0.0697 to 0.820,  $p=0.034$ ), indicating that intra-articular OCs may contribute to the enhanced osteoclastogenic potential within the affected joints.

## Discussion

Our study confirmed systemic enhancement of osteoclastogenesis in arthritis, particularly RA. Increased osteoclastogenic potential of PBMC positively correlated with proinflammatory mediators in circulation and inflammation intensity, confirming that inflammation is a trigger for enhanced OC activity. OCPs are contained among both PBMC and SFMC, but not with the same frequency in RA and PsA, and even within the PBMC and SFMC of the same patient. We concluded that circulatory and intra-articular compartments possess distinct profiles of osteoclastogenic factors and OC-inducing capacity.

Higher number of OCs differentiated from PBMC of RA and PsA patients compared with controls. Moreover, more differentiated OCs and induced *RANK* expression were found in RA compared with PsA patients, reflecting high osteoclastogenic potential of circulatory compartment. Human OCPs are present at low frequency in normal PB within the monocyte population [1], and increase in number and osteoclastogenic potential in arthritis [9, 10], but this is the first study to include control subjects and patients suffering from different forms of arthritis, using paired PBMC and SFMC arthritic samples for osteoclastogenic assay.

In addition to the systemic changes, inflamed joints are marked with severe lymphocyte infiltration especially in RA, with the predominance of T lymphocytes within the SF [11]. Therefore, by plating the same number of SFMC for osteoclastogenic cultures as for PBMC, we included lower number of OCPs, giving us the overall lower number of *ex vivo* matured OCs and no difference between RA and PsA. Bone loss in RA and PsA occurs to the similar extent, either locally in the peripheral joints, or systemically with loss of BMD [2, 12]. However, in the functional assay SF of PsA patients showed more potent OC-inducing activity compared with RA, paralleled by higher *RANKL* and *RANK* expression, corroborating that PsA involves specific change in RANKL/RANK axis [5]. Ritchlin et al demonstrated intense RANKL expression throughout the synovial lining layer, implicating enhanced RANKL-mediated osteoclastogenesis in PsA [10].

Proinflammatory profile in our patients included the highest level of CCL2 in RA patients, and positive correlation with the number of PBMC derived OCs. Also, CCL2 was highly induced with OC maturation, with the positive correlation between OC CCL2 expression and the number of OCs differentiated from SFMC. It has been shown, using CCL2-deficient mice and human PBMC, that CCL2 regulates OC differentiation in an autocrine/paracrine manner and that OCPs express CCL2 receptors, CCR2 and CCR4

[13, 14]. Kim et al proposed that RANKL-stimulated OC-lineage cells send a chemokine signal to attract OCPs to the site of RANKL signaling, resulting in cell fusion to multinuclear OCs [15].

Association of proinflammatory factors with osteoclastogenic potential confirmed that they play a role not only in creating inflammatory environment but also in inducing osteoresorption. IL-17 and IL-18 were both elevated systemically and, together with TNF- $\alpha$ , the most prominent in SF of RA patients. TNF- $\alpha$  was not increased in serum, but overall concentrations in all groups were very low. TNF- $\alpha$  and IL-17 are able to induce RANK expression on human OCPs and OC differentiation [16, 17], and are substantial factors in inflammation-mediated bone destruction [18, 19]. Results for IL-18 effects on osteoclastogenesis are still controversial, suggesting both anti-osteoclastogenic [20] and pro-osteoclastogenic effects, via induction of TNF and RANKL in synovial T lymphocytes and fibroblast-like synoviocytes [21, 22]. Intra-articular osteoclastogenic milieu, observed in our study, may support OCPs not only in SF but also on bone surfaces, causing periarticular bone erosions [10]. Moreover, we believe that lack of correlation between proinflammatory mediators and number of OCs differentiated from SFMC could be explained by the fact that those mediators act on the pannus-bone interface and enhance OCPs attachment to the resorption lacunas where they are not available for harvesting by SF aspiration.

Besides inflammatory mediators, we found increased expression of *FasL* in PBMC of PsA patients and a positive correlation with the number of PBMC-derived OCs. A disease-modifying drug SSZ was able to reduce FasL in SF of treated patients. Although Fas/Fas ligand system is involved in the regulation of bone homeostasis, the role in arthritis is still controversial [7, 23, 24]. Resident synoviocytes and infiltrating immune cells are resistant to FasL-mediated apoptosis, contributing to joint lesions [24]. Increased expression could represent a compensatory mechanism to induce apoptosis of autoreactive T lymphocytes in autoimmune conditions.

## **Conclusions**

In conclusion, our study revealed disease-specific changes despite high heterogeneity of SF milieu between patients, reflecting chronic nature of the disease and great variability in SF content [11]. In particular, RA patients have the highest values of inflammatory mediators in both serum and SF, implicating alternate osteoclastogenic pathways independent of RANKL and TNF- $\alpha$  [25]. On the other hand, PsA involves specific increase in *RANKL/RANK* expression in synovial compartment, creating potent osteoclastogenic environment in the affected joints. Our findings indicate arthritis-specific mediators associated to the form of arthritis, which may be clinically relevant for the development of diagnostic or therapeutic strategies targeting proinflammatory and osteoclastogenic effects of arthritis.

## **Acknowledgments**

This work was supported by the grants from the Croatian Ministry of Science, Education and Sports (108-1080229-0140, 108-1080229-0142, and 108-1080229-0341).

We thank Prof. Vedran Katavic for critically revising manuscript and Mrs. Katerina Zrinski-Petrovic for her technical assistance.

## **Conflict of Interest**

The authors declare that they have no conflict of interest.

## References

1. Lari R, Kitchener PD, Hamilton JA (2009) The proliferative human monocyte subpopulation contains osteoclast precursors. *Arthritis Res Ther* 11:R23
2. Roux C (2011) Osteoporosis in inflammatory joint diseases. *Osteoporos Int* 22:421–33
3. Grčević D, Lukić IK, Kovačić N, Ivčević S, Katavić V, Marušić A (2006) Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos. *Clin Exp Immunol* 146:146–58
4. Colucci S, Brunetti G, Cantatore FP et al (2007) Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. *J Pathol* 212:47–55
5. Dalbeth N, Pool B, Smith T et al (2010) Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. *Arthritis Res Ther* 12:R164
6. Lorenzo J, Horowitz M, Choi Y (2008) Osteoimmunology: interactions of the bone and immune system. *Endocr Rev* 29:403–40
7. Grčević D, Jajić Z, Kovačić N, Lukić IK, Velagić V, Grubišić F, Ivčević S, Marušić A (2010) Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. *J Rheumatol* 37:246–56
8. Schett G, Saag KG, Bijlsma JW (2010) From bone biology to clinical outcome: state of the art and future perspectives. *Ann Rheum Dis* 69:1415–9
9. Komano Y, Nanki T, Hayashida K, Taniguchi K, Miyasaka N (2006) Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts. *Arthritis Res Ther* 8:R152
10. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM (2003) Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. *J Clin Invest* 111:821–31



11. Bugatti S, Manzo A, Bombardieri M, Vitolo B, Humby F, Kelly S, Montecucco C, Pitzalis C (2011) Synovial tissue heterogeneity and peripheral blood biomarkers. *Curr Rheumatol Rep* 13:440–8
12. Finzel S, Engbrecht M, Engelke K, Stach C, Schett G (2011) A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis. *Ann Rheum Dis* 70:122–7
13. Miyamoto K, Ninomiya K, Sonoda KH et al (2009) MCP-1 expressed by osteoclasts stimulates osteoclastogenesis in an autocrine/paracrine manner. *Biochem Biophys Res Commun* 383:373–7
14. Kim MS, Magno CL, Day CJ, Morrison NA (2006) Induction of chemokines and chemokine receptors CCR2b and CCR4 in authentic human osteoclasts differentiated with RANKL and osteoclast like cells differentiated by MCP-1 and RANTES. *J Cell Biochem* 97:512–8
15. Kim MS, Day CJ, Morrison NA (2005) MCP-1 is induced by receptor activator of nuclear factor- $\kappa$ B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. *J Biol Chem* 280:16163–9
16. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y (2001) Tumor necrosis factor- $\alpha$  (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. *J Biol Chem* 276:563–8
17. Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura Y, McClanahan T, Bowman EP (2010) Interleukin-17A upregulates receptor activator of NF- $\kappa$ B on osteoclast precursors. *Arthritis Res Ther* 12:R29
18. Toussiot E (2012) The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. *Inflamm Allergy Drug Targets* 11:159–68
19. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. *EMBO J* 10:4025–31
20. Morita Y, Kitaura H, Yoshimatsu M, Fujimura Y, Kohara H, Eguchi T, Yoshida N (2010) IL-18 inhibits TNF- $\alpha$ -induced osteoclastogenesis possibly via a T cell-independent mechanism in synergy with IL-12 in vivo. *Calcif Tissue Int* 86:242–8

21. Zhang W, Cong XL, Qin YH, He ZW, He DY, Dai SM (2013) IL-18 upregulates the production of key regulators of osteoclastogenesis from fibroblast-like synoviocytes in rheumatoid arthritis. *Inflammation* 36:103–9
22. Dai SM, Nishioka K, Yudoh K (2004) Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. *Ann Rheum Dis* 63:1379–86
23. Park H, Jung YK, Park OJ, Lee YJ, Choi JY, Choi Y (2005) Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis. *J Immunol* 175:7193–201
24. Peng SL (2006) Fas (CD95)-related apoptosis and rheumatoid arthritis. *Rheumatology (Oxford)* 45:26–30
25. Dickerson TJ, Suzuki E, Stanecki C, Shin HS, Qui H, Adamopoulos IE (2012) Rheumatoid and pyrophosphate arthritis synovial fibroblasts induce osteoclastogenesis independently of RANKL, TNF and IL-6. *J Autoimmun* 39:36–76

**Table 1.** Selected demographic and clinical characteristics of control subjects and patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA)




<b>Characteristic<sup>a</sup></b>	<b>Control</b>	<b>RA</b>	<b>PsA</b>
<b>Number of subjects</b>	14 <sup>b</sup>	10 <sup>c</sup>	10 <sup>c</sup>
<b>Male/Female</b>	5/9	3/7	3/7
<b>Age, years</b>	59.7±14.7	55.8±9.1	48.3±11.5
<b>Disease duration, years</b>	NA	12.1±12.6	11.2±10.2
<b>ESR, mm/hour</b>	9.0±4.0	51.4±37.8	32.7±20.5
<b>CRP, mg/liter</b>	2.7±0.8	57.1±23.9	38.3±21.2
<b>Swollen joint count (28-joint score)</b>	NA	6.4±4.1	4.8±4.2
<b>Tender joint count (28-joint score)</b>	NA	13.3±7.5	9.9±7.4
<b>DAS28 (0-10)</b>	NA	6.0±0.9	5.1±1.3
<b>BASDAI (0-10)</b>	NA	NA	3.3±3.0
<b>MASES (0-13)</b>	NA	NA	4.2±4.6
<b>Larsen score for RA (0-4); Radiological score of sacroileitis for PsA (0-4)</b>	NA	2.7±0.5	2.8±0.4
<b>NSAIDs</b>	NA	7/10	6/10
<b>DMARDs</b>	NA	5/10	5/10
<b>Corticosteroids</b>	NA	1/10	2/10

<sup>a</sup> Values are presented as mean ± standard deviation. ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28, Disease Activity Score including a 28-joint count; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; NSAIDs, non-steroid anti-inflammatory drugs; DMARDs, disease-modifying antirheumatic drugs; NA, not applicable. <sup>b</sup> Sera of 14 control patients were analyzed by ELISA, whereas 8 PBMC control samples were subjected to osteoclastogenic assay. <sup>c</sup> Patients with RA and PsA were not treated with biological agents.

## Figure legends



**Fig. 1** Osteoclastogenic cultures of peripheral blood mononuclear cells (PBMC) and synovial fluid-derived mononuclear cells (SFMC) from arthritic patients

(a) Osteoclasts (OCs) were identified as TRAP-positive cells with  $\geq 2$  nuclei/cell (representative cultures). (b) Number of TRAP-positive OCs/well differentiated from control subjects (PBMC), and arthritic patients with RA and PsA (PBMC and SFMC), presented as median (IQR). (c) Expression of OC-specific genes in PBMC (PB) and SFMC (SF) at culture days 0 and 10, presented as RNA relative quantity (median (IQR)). Group-to-group comparisons were performed using Mann-Whitney test, p values  $\leq 0.05$  are shown. *RANK*, receptor activator of nuclear factor- $\kappa$ B; *cFMS*, macrophage colony-stimulating factor receptor; *TRAP*, tartrate-resistant acid phosphatase.




**Fig. 2** Proinflammatory/immunoregulatory mediators in circulatory and intra-articular compartments of arthritic patients

(a) Mediators were analyzed in serum and synovial fluid (SF) at the protein level by ELISA, and (b) in peripheral blood mononuclear cells (PBMC) and synovial fluid-derived mononuclear cells (SFMC) at the gene expression level by qPCR. Values are presented as RNA relative quantity (median (IQR)) for each group. Group-to-group comparisons were performed using Mann-Whitney test, p values  $\leq 0.05$  are shown. CCL2, CC chemokine ligand 2; TNF- $\alpha$ , tumor necrosis factor  $\alpha$ ; FasL, Fas ligand; IL, interleukin.



**Fig. 3** Correlation between osteoclastogenic potential and inflammation indicators




Significant correlations were found for the number of osteoclasts (OCs) differentiated from peripheral blood mononuclear cells (PBMC) with erythrocyte sedimentation rate (ESR), as indicator of systemic inflammation, and osteoclastogenic mediators: serum concentration of CC chemokine ligand 2 (CCL2) and PBMC gene expression of interleukin-18 (*IL-18*) and Fas ligand (*FasL*). Values were correlated using rank correlation and Spearman's coefficient  $\rho$  (95% confidence interval (CI) for  $\rho$ ), p values  $\leq 0.05$  are shown.






**Fig. 4** Comparison of synovial fluid (SF) osteoclastogenic effect from patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA)

(a) Osteoclastogenic effect of SF in a co-culture model of sorted osteoclasts (OC) progenitors ( $CD3^-CD19^-CD56^-CD11b^+CD14^+$  cells from control peripheral blood mononuclear cells (PBMC) samples (n=5)), differentiated ( $50000\text{ cells/cm}^2$ ) with receptor activator of nuclear factor  $\kappa B$  ligand (RANKL) and macrophage colony-stimulating factor (M-CSF), and individual SFs from RA or PsA patients (in 40% volume proportion). (b) Number of TRAP-positive OCs/well differentiated in the co-culture model of sorted OC progenitors and SFs from RA or PsA patients. Dashed line presents number of OCs/well differentiated in control (Ctrl) cultures that were not treated with arthritic SF. (c) Gene expression of *RANKL* in PBMC and synovial fluid-derived mononuclear cells (SFMC) of patients with RA and PsA. Values are presented as median (IQR). Group-to-group comparisons were performed using Mann-Whitney test, p values  $\leq 0.05$  are shown. TRAP, tartrate-resistant acid phosphatase.



**Fig. 5** Discriminatory ability of osteoclast (OC) differentiation potential and proinflammatory mediators between arthritic and control samples

Receiver operating characteristic (ROC) curves for the number of OCs differentiated from peripheral blood mononuclear cells (PBMC), serum concentration of CC chemokine ligand 2 (CCL2), and PBMC gene expression of interleukin-18 (*IL-18*) and Fas ligand (*FasL*). Diagnostic efficacy for those values was assessed using the sensitivity and specificity at a cut-off point. ROC curve analyses, p values (for area under curve = 0.5)  $\leq 0.05$  are shown.



**Supplementary table 1.** Clinical variables recorded in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA)

<b>Variable</b>	<b>RA</b>	<b>PsA</b>
duration of the disease and symptoms (years)	+	+
patient assessment of pain, fatigue and disease activity (VAS)	+	+
patient assessment of the duration (min) and intensity of morning stiffness (VAS)	+	+
patient assessment of spinal pain (VAS)	NA	+
patient assessment of enthesial pain (VAS)	NA	+
physician assessment of disease activity (VAS)	+	+
laboratory variables: erythrocyte sedimentation rate (mm/h), C-reactive protein (mg/L), HLA genotyping	+	+
joint scores for tenderness and swelling (28-joint score)	+	+
DAS28 (0-10)	+	+
BASDAI (0-10)	NA	+
MASES (0-13)	NA	+
Larsen score (0-4)	+	NA
radiological score of sacroileitis (0-4)	NA	+
radiological assessment of spondylitis for PsA (yes/no)	NA	+
radiological assessment of erosive changes of wrists, small joints of the hand and foot (yes/no)	NA	+
dactylitis, psoriasis of the nails and skin (yes/no)	NA	+

<sup>a</sup> VAS, visual analog scale; DAS28, Disease activity score including a 28-joint count; BASDAI, Bath ankylosing spondylitis disease activity index; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; radiological score of sacroileitis (Jajic I. Ann Rheum Dis 1968); NA, not applicable.

**Supplementary table 2.** TaqMan assays used for qPCR analysis

<b>Gene<sup>a</sup></b>	<b>Gene symbol</b>	<b>Assay ID</b>
<i><b>RANK</b></i>	<i>TNFRSF11A</i>	Hs00187189_m1
<i><b>cFMS</b></i>	<i>CSF1R</i>	Hs00234622_m1
<i><b>TRAP</b></i>	<i>ACP5</i>	Hs00356261_m1
<i><b>TNF-<math>\alpha</math></b></i>	<i>TNF</i>	Hs99999043_m1
<i><b>CCL2</b></i>	<i>CCL2</i>	Hs00234140_m1
<i><b>IL-17</b></i>	<i>IL17A</i>	Hs00174383_m1
<i><b>IL-18</b></i>	<i>IL18</i>	Hs00155517_m1
<i><b>FasL</b></i>	<i>FASLG</i>	Hs00181255_m1
<i><b>RANKL</b></i>	<i>TNFSF11</i>	Hs00243522_m1
<i><b>GAPDH</b></i>	<i>GAPDH</i>	Hs99999905_m1

<sup>a</sup>Assays used for qPCR analysis were commercially available and used in accord to the manufacturer recommendation (Applied Biosystems).